Risk Stratification of Heart Failure in Cardiomyopathies. (EARLY-MYO-HF)
Cardiomyopathy With Unknown Etiology
About this trial
This is an interventional diagnostic trial for Cardiomyopathy With Unknown Etiology focused on measuring Cardiomyopathy, Heart Failure, Cardiac Magnetic Resonance
Eligibility Criteria
Inclusion Criteria:
- Participants with cardiomyopathy diagnosed by medical history, clinical symptoms, laboratory tests including ECG, echocardiography.
- no known etiology of cardiomyopathy was confirmed.
Exclusion Criteria:
- with contraindications of magnetic resonance include: 1, participants with cardiac pacemakers and nerve stimulator; 2, participants who have done aneurysm surgery and intracranial with aneurysm folder; 3, participants with the metal foreign body in the eye; 4, pregnant women; 5, critically ill participants need life support systems; 6, epilepsy participants; 7, claustrophobic participants;.
- participants who are <15 years of age or >75 years.
- participants who have the contraindication use of contrast media: glomerular filtration rate <30 ml/min
Sites / Locations
- Renji Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Placebo Comparator
Placebo Comparator
Experimental
with CMR confirmed etiology
etiology unconfirmed without acute HF
etiology unconfirmed with acute HF
etiology confirmed with acute HF
Participants who were identified with cardiac magnetic resonance (CMR) in etiology were treated with drug including etiologic treatment,anti-myocardial remodeling.
Participants who were not identified with cardiac magnetic resonance (CMR) in etiology and without acute hearts failure (HF) were treated with drug with anti-myocardial remodeling.
Participants who were not identified with CMR in etiology but with acute hearts failure were treated with drug with anti-myocardial remodeling,anti-acute heart failure.
Participants who were identified with CMR in etiology but with acute hearts failure were treated with drug with Etiological, anti-remodeling and symptom treatment.